Evidence for Transformation of Glucagon-Like Immunoreactivity of Gut into Pancreatic Glucagon In Vivo
| Autor: | Gy Tamás, Maria Guóth, Korányi L, J Szabó, Angela Török, F Péterfy |
|---|---|
| Rok vydání: | 1981 |
| Předmět: |
Blood Glucose
endocrine system medicine.medical_specialty Swine Endocrinology Diabetes and Metabolism Endogeny Hypoglycemia Biology Proglucagon Glucagon In vivo Internal medicine Diabetes mellitus Internal Medicine medicine Animals Insulin Secretion Intestinal Mucosa Protein Precursors Pancreas digestive oral and skin physiology Biological activity medicine.disease Endocrinology Somatostatin hormones hormone substitutes and hormone antagonists |
| Zdroj: | Diabetes. 30:792-794 |
| ISSN: | 1939-327X 0012-1797 |
| DOI: | 10.2337/diab.30.9.792 |
| Popis: | SUMMARY The effect of gut glucagon-like immunoreactivity (GLI) devoid of pancreatic glucagon was studied in piglets. All glucagon-like peptides with an accessible C-terminal were removed from the gut extract by specific antibodies reacting with the C-terminal of the glucagon molecule. Endogenous secretion of pancreatic and gut glucagon was blocked by somatostatin infusion, and then the purified gut glucagon preparation was infused. The latter prevented the hypoglycemia resulting from somatostatin infusion, and increased the glucagon level detectable by C-terminal specific antibodies in the blood of the animals. This rise was significant statistically from the 30th min of GLI administration (26.7 ± 7.2 pg/ml versus 137.0 ± 67.0 pg/ml; P < 0.05) and increased until the end of the infusion (90th min, 218 ± 60 pg/ml; P < 0.005). It has been suggested that, owing to the in vivo enzymatic degradation of the infused gut glucagon, biologically active "pancreatic" glucagon fractions are formed extracellularly. DIABETES 30:792-794, September 1981. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|